Precirix
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Burgemeester Etienne Demunterlaan 1, Bru...Phone Number
+32 24799360Website
www.precirix.comRevenue
$11.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Precirix
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix's technology also allows for a theragnostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Precirix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Precirix is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Precirix
Website visits: Recent activity has been detected on your website
Precirix, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Precirix recently announced quarterly report
Click to see if Precirix had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Precirix has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Precirix launches new products
Funding: Get notified immidiatlly once Precirix has new funding data
Recommended Actions
Find VP level buyers at Precirix
Find more new buyers
Company Profile Activity
Activity Insights
Precirix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Precirix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Precirix.
Precirix financials insights
Gather financial insights about Precirix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$29.8M
2022
Series B
$88M
Precirix Tech Stack
A closer look at the technologies used by Precirix
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Left Company
Executive Move
Lateral Move
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
Funding
Precirix News & Media
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
BRUSSELS, March 16, 2022 /PRNewswire/ -- Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads....Precirix Dosed First Patients in Phase I/II Clinical Study Evaluating CAM-H2 in HER2-Positive Metastatic Cancer
BRUSSELS--(BUSINESS WIRE)-- #CAMH2--Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announces that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. This is a major milestone in the company’s development of its lead therapeutic asset. The Phase I/II trial (NCT04467515) evaluates safety, tumor uptake, tumor retention and early signs of antitumor activity of sinPrecirix partners with Evergreen to expand North American clinical trial supply
BRUSSELS and JERSEY CITY, N.J., April 28, 2021 /PRNewswire/ -- Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, Inc., a radiopharmaceutical contract manufacturer, today announced that the companies have...Dr. Matthias Friebe joins Camel-IDS as acting Chief Technology Officer.
Brussels, Belgium - Camel-IDS, a private biotechnology company developing novel radioligand therapies in oncology, announces the appointment of Dr. Matthias Friebe as acting Chief Technology Officer (CTO). Dr. Friebe will be responsible for defining and e
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Precirix
Sign Up For FreeTo access detailed company insights
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one produc... Read More
